Some authors found that mouse B cells modulate the response to low-dose oxaliplatin, promoting tumor-directed CD8+ cytotoxic T cells (CTL) activation: three different mouse PC-models were oxaliplatin-resistant unless genetically or pharmacologically depleted of B cells. The gene discussed is CD8A; the disease is neoplasm.